⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
globenewswire.com
AKTX
Akari Therapeutics to Present at the 2026 Biotech Showcase
globenewswire.com
AKTX
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
globenewswire.com
AKTX
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
globenewswire.com
AKTX
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
globenewswire.com
AKTX
Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
globenewswire.com
AKTX
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
globenewswire.com
AKTX
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
globenewswire.com
AKTX
Hyaluronic Acid Market Forecasts Report 2025-2030: Opportunities Driven by Demand for Non-surgical Cosmetic Procedures and Interest in Anti-aging Solutions
globenewswire.com
ABBV
SNY
AKTX
Akari Therapeutics Announces Release of the Next CEO Corner Segment
globenewswire.com
AKTX